Trial Outcomes & Findings for A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis (NCT NCT01519089)

NCT ID: NCT01519089

Last Updated: 2015-08-13

Results Overview

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at Week 16 relative to Baseline.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

95 participants

Primary outcome timeframe

Week 16

Results posted on

2015-08-13

Participant Flow

Participant milestones

Participant milestones
Measure	CP-690,550 5 mg BID CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.
Overall Study STARTED	47	48
Overall Study Received Treatment	47	47
Overall Study COMPLETED	40	33
Overall Study NOT COMPLETED	7	15

Reasons for withdrawal

Reasons for withdrawal
Measure	CP-690,550 5 mg BID CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.
Overall Study Adverse Event	4	4
Overall Study Lack of Efficacy	0	2
Overall Study Lost to Follow-up	1	0
Overall Study Withdrawal by Subject	0	2
Overall Study Other	2	6
Overall Study Not received study drug	0	1

Baseline Characteristics

A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	CP-690,550 5 mg BID n=47 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=47 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=94 Participants Total of all reporting groups
Age, Continuous	50.9 years STANDARD_DEVIATION 11.8 • n=5 Participants	46.4 years STANDARD_DEVIATION 10.8 • n=7 Participants	48.7 years STANDARD_DEVIATION 11.5 • n=5 Participants
Sex: Female, Male Female	8 Participants n=5 Participants	8 Participants n=7 Participants	16 Participants n=5 Participants
Sex: Female, Male Male	39 Participants n=5 Participants	39 Participants n=7 Participants	78 Participants n=5 Participants

PRIMARY outcome

Timeframe: Week 16

Population: Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16	62.8 Percentage of participants	72.7 Percentage of participants	67.8 Percentage of participants

PRIMARY outcome

Timeframe: Week 16

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16	67.4 Percentage of participants	68.2 Percentage of participants	67.8 Percentage of participants

PRIMARY outcome

Timeframe: Week 16

Population: Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.

ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=4 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=8 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=12 Participants (=sum across Arm/Groups)
Proportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16	100 Percentage of participants	100 Percentage of participants	100 Percentage of participants

PRIMARY outcome

Timeframe: Baseline to Follow-up

Population: Participants treated with at least 1 dose of study drugs.

Adjudicated cardiovascular events were assessed by investigators as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; specific requirements vary with the event requiring adjudication.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=47 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=47 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=94 Participants (=sum across Arm/Groups)
Number of Participants With Adjudicated Cardiovacular Events	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Baseline to Follow-up

Population: Participants treated with at least 1 dose of study drugs.

For all biopsies of potentially malignant tumors, suspicious lymphadenopathy, or possible extranodal LPD, the study site requested the pathologist to send the original slides used to make the definitive diagnosis, ancillary study reports, and the pathologist's report to the central laboratory for a blinded review by a central pathologist.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=47 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=47 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=94 Participants (=sum across Arm/Groups)
Number of Participants With Malignancy Events _Week 0 Through Follow-up Number of participants with any malignancy events	0 Participants	0 Participants	0 Participants
Number of Participants With Malignancy Events _Week 0 Through Follow-up Malignancy excluding non-melanoma skin cancer	0 Participants	0 Participants	0 Participants
Number of Participants With Malignancy Events _Week 0 Through Follow-up Lymphoma/Lymphoproliferative disorders (LPD)	0 Participants	0 Participants	0 Participants
Number of Participants With Malignancy Events _Week 0 Through Follow-up Melanoma	0 Participants	0 Participants	0 Participants
Number of Participants With Malignancy Events _Week 0 Through Follow-up Non-melanoma skin cancer	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 20, 28, 40, 52

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response Week 2	2.3 Percentage of participants	4.5 Percentage of participants	3.4 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response Week 4	7.0 Percentage of participants	22.7 Percentage of participants	14.9 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response Week 8	41.9 Percentage of participants	54.5 Percentage of participants	48.3 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response Week 12	60.5 Percentage of participants	70.5 Percentage of participants	65.5 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response Week 20	67.4 Percentage of participants	63.6 Percentage of participants	65.5 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response Week 28	69.8 Percentage of participants	65.9 Percentage of participants	67.8 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response Week 40	69.8 Percentage of participants	63.6 Percentage of participants	66.7 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response Week 52	62.8 Percentage of participants	63.6 Percentage of participants	63.2 Percentage of participants

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least a 50 percent (%) reduction in PASI at the each visit relative to Baseline.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response Week 8	60.5 Percentage of participants	81.8 Percentage of participants	71.3 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response Week 2	9.3 Percentage of participants	22.7 Percentage of participants	16.1 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response Week 4	34.9 Percentage of participants	56.8 Percentage of participants	46.0 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response Week 12	81.4 Percentage of participants	84.1 Percentage of participants	82.8 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response Week 16	76.7 Percentage of participants	79.5 Percentage of participants	78.2 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response Week 20	79.1 Percentage of participants	75.0 Percentage of participants	77.0 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response Week 28	90.7 Percentage of participants	72.7 Percentage of participants	81.6 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response Week 40	88.4 Percentage of participants	79.5 Percentage of participants	83.9 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response Week 52	90.7 Percentage of participants	68.2 Percentage of participants	79.3 Percentage of participants

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90 percent (%) reduction in PASI at the each visit relative to Baseline.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response Week 8	16.3 Percentage of participants	29.5 Percentage of participants	23.0 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response Week 2	0.0 Percentage of participants	0.0 Percentage of participants	0.0 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response Week 4	4.7 Percentage of participants	13.6 Percentage of participants	9.2 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response Week 12	37.2 Percentage of participants	45.5 Percentage of participants	41.4 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response Week 16	37.2 Percentage of participants	54.5 Percentage of participants	46.0 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response Week 20	58.1 Percentage of participants	56.8 Percentage of participants	57.5 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response Week 28	55.8 Percentage of participants	45.5 Percentage of participants	50.6 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response Week 40	58.1 Percentage of participants	47.7 Percentage of participants	52.9 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response Week 52	51.2 Percentage of participants	47.7 Percentage of participants	49.4 Percentage of participants

SECONDARY outcome

Timeframe: Week 16

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'	8.0 Week Interval 8.0 to 12.0	8.0 Week Interval 4.0 to 12.0	8.0 Week The 95 percent confidence interval could not be constructed.

SECONDARY outcome

Timeframe: Week 16

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Time to Achieve a Psoriasis Area and Severity Index 75 (PASI75) Response	12.0 Week Interval 8.0 to 16.0	8.0 Week Interval 8.0 to 12.0	12.0 Week Interval 8.0 to 12.0

SECONDARY outcome

Timeframe: Week 16

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Time to Achieve a Psoriasis Area and Severity Index 50 (PASI50) Response	8.0 Week Interval 4.0 to 12.0	4.0 Week Interval 4.0 to 8.0	8.0 Week Interval 4.0 to 8.0

SECONDARY outcome

Timeframe: Week 16

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least 90% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Time to Achieve a Psoriasis Area and Severity Index 90 (PASI90) Response	NA Week Interval 12.0 to The median time could not be computed because fewer than half of the subjects achieved a PASI90 response.	12.0 Week Interval 12.0 to 16.0	16.0 Week Interval 12.0 to The 95 percent upper limit could not be computed due to the limited analysis duration up to Week 16.

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score Week 8 (n=43, 41, 84)	0.0 Percentage of participants	0.0 Percentage of participants	0.0 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score Week 2	2.3 Percentage of participants	0.0 Percentage of participants	1.1 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score Week 4	0.0 Percentage of participants	2.3 Percentage of participants	1.1 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score Week 12 (n=43, 41, 84)	0.0 Percentage of participants	2.4 Percentage of participants	1.2 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score Week 16 (n=43, 40, 83)	0.0 Percentage of participants	2.5 Percentage of participants	1.2 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score Week 20 (n=43, 39, 82)	0.0 Percentage of participants	0.0 Percentage of participants	0.0 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score Week 28 (n=43, 39, 82)	0.0 Percentage of participants	0.0 Percentage of participants	0.0 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score Week 40 (n=41, 38, 79)	0.0 Percentage of participants	0.0 Percentage of participants	0.0 Percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score Week 52 (n=39, 32, 71)	0.0 Percentage of participants	0.0 Percentage of participants	0.0 Percentage of participants

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Week 28 (n=43, 39, 82)	-21.77 Units on a scale Standard Deviation 10.196	-21.46 Units on a scale Standard Deviation 10.503	-21.62 Units on a scale Standard Deviation 10.280
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Week 2	-5.18 Units on a scale Standard Deviation 5.898	-7.36 Units on a scale Standard Deviation 6.428	-6.28 Units on a scale Standard Deviation 6.232
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Week 4	-10.40 Units on a scale Standard Deviation 7.518	-13.16 Units on a scale Standard Deviation 8.739	-11.79 Units on a scale Standard Deviation 8.229
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Week 8 (n=43, 41, 84)	-15.95 Units on a scale Standard Deviation 8.392	-19.90 Units on a scale Standard Deviation 10.741	-17.88 Units on a scale Standard Deviation 9.756
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Week 12 (n=43, 41, 84)	-18.91 Units on a scale Standard Deviation 8.918	-21.68 Units on a scale Standard Deviation 11.598	-20.26 Units on a scale Standard Deviation 10.344
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Week 16 (n=43, 40, 83)	-19.53 Units on a scale Standard Deviation 9.094	-22.06 Units on a scale Standard Deviation 12.606	-20.75 Units on a scale Standard Deviation 10.935
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Week 20 (n=43, 39, 82)	-20.95 Units on a scale Standard Deviation 9.239	-22.18 Units on a scale Standard Deviation 12.045	-21.53 Units on a scale Standard Deviation 10.617
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Week 40 (n=41, 38, 79)	-22.20 Units on a scale Standard Deviation 10.181	-21.18 Units on a scale Standard Deviation 10.229	-21.71 Units on a scale Standard Deviation 10.151
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Week 52 (n=39, 32, 71)	-21.96 Units on a scale Standard Deviation 9.621	-22.11 Units on a scale Standard Deviation 10.598	-22.03 Units on a scale Standard Deviation 10.000

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 8: Erythema (Upper Limbs) (n=43, 41, 84)	-1.5 Units on a scale Standard Deviation 0.93	-1.6 Units on a scale Standard Deviation 0.98	-1.5 Units on a scale Standard Deviation 0.95
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 52: Scaling (Head/Neck) (n=39, 32, 71)	-1.8 Units on a scale Standard Deviation 0.98	-1.6 Units on a scale Standard Deviation 1.08	-1.7 Units on a scale Standard Deviation 1.02
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 4: Induration (Head/Neck)	-0.7 Units on a scale Standard Deviation 0.89	-1.2 Units on a scale Standard Deviation 1.09	-1.0 Units on a scale Standard Deviation 1.02
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 4: Induration (Upper Limbs)	-1.1 Units on a scale Standard Deviation 0.86	-1.0 Units on a scale Standard Deviation 0.85	-1.0 Units on a scale Standard Deviation 0.85
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 4: Induration (Lower Limbs)	-1.0 Units on a scale Standard Deviation 0.90	-1.2 Units on a scale Standard Deviation 0.98	-1.1 Units on a scale Standard Deviation 0.94
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 4: Scaling (Head/Neck)	-0.8 Units on a scale Standard Deviation 0.86	-1.2 Units on a scale Standard Deviation 0.99	-1.0 Units on a scale Standard Deviation 0.95
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 4: Scaling (Upper Limbs)	-0.9 Units on a scale Standard Deviation 0.70	-1.2 Units on a scale Standard Deviation 0.86	-1.0 Units on a scale Standard Deviation 0.79
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 4: Scaling (Trunk)	-0.9 Units on a scale Standard Deviation 0.71	-1.3 Units on a scale Standard Deviation 0.95	-1.1 Units on a scale Standard Deviation 0.87
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 4: Scaling (Lower Limbs)	-0.8 Units on a scale Standard Deviation 0.72	-1.3 Units on a scale Standard Deviation 0.96	-1.1 Units on a scale Standard Deviation 0.89
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 8: Erythema (Head/Neck) (n=43, 41, 84)	-1.4 Units on a scale Standard Deviation 1.13	-1.6 Units on a scale Standard Deviation 1.03	-1.5 Units on a scale Standard Deviation 1.08
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 8: Erythema (Trunk) (n=43, 41, 84)	-1.7 Units on a scale Standard Deviation 0.91	-1.9 Units on a scale Standard Deviation 0.93	-1.8 Units on a scale Standard Deviation 0.92
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 8: Erythema (Lower Limbs) (n=43, 41, 84)	-1.5 Units on a scale Standard Deviation 0.91	-1.7 Units on a scale Standard Deviation 0.91	-1.6 Units on a scale Standard Deviation 0.91
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 8: Induration (Upper Limbs) (n=43, 41, 84)	-1.6 Units on a scale Standard Deviation 0.93	-1.6 Units on a scale Standard Deviation 0.89	-1.6 Units on a scale Standard Deviation 0.91
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 8: Scaling (Head/Neck) (n=43, 41, 84)	-1.3 Units on a scale Standard Deviation 0.90	-1.5 Units on a scale Standard Deviation 1.03	-1.4 Units on a scale Standard Deviation 0.96
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 12: Induration (Upper Limbs) (n=43, 41, 84)	-1.7 Units on a scale Standard Deviation 0.94	-1.8 Units on a scale Standard Deviation 0.99	-1.7 Units on a scale Standard Deviation 0.96
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 12: Induration (Trunk) (n=43, 41, 84)	-2.0 Units on a scale Standard Deviation 1.01	-2.0 Units on a scale Standard Deviation 1.00	-2.0 Units on a scale Standard Deviation 1.00
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 12: Induration (Lower Limbs) (n=43, 41, 84)	-1.9 Units on a scale Standard Deviation 0.91	-1.9 Units on a scale Standard Deviation 1.06	-1.9 Units on a scale Standard Deviation 0.98
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 16: Erythema (Trunk) (n=43, 40, 83)	-2.1 Units on a scale Standard Deviation 1.10	-2.0 Units on a scale Standard Deviation 1.07	-2.0 Units on a scale Standard Deviation 1.08
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 16: Erythema (Lower Limbs) (n=43, 40, 83)	-2.0 Units on a scale Standard Deviation 1.03	-1.9 Units on a scale Standard Deviation 0.94	-2.0 Units on a scale Standard Deviation 0.99
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 16: Scaling (Upper Limbs) (n=43, 40, 83)	-1.5 Units on a scale Standard Deviation 0.93	-1.7 Units on a scale Standard Deviation 1.05	-1.6 Units on a scale Standard Deviation 0.99
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 16: Scaling (Trunk) (n=43, 40, 83)	-1.6 Units on a scale Standard Deviation 0.96	-1.8 Units on a scale Standard Deviation 1.09	-1.7 Units on a scale Standard Deviation 1.02
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 16: Scaling (Lower Limbs) (n=43, 40, 83)	-1.6 Units on a scale Standard Deviation 0.93	-1.8 Units on a scale Standard Deviation 1.06	-1.7 Units on a scale Standard Deviation 1.00
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 20: Erythema (Head/Neck) (n=43, 39, 82)	-1.8 Units on a scale Standard Deviation 1.15	-1.6 Units on a scale Standard Deviation 0.96	-1.7 Units on a scale Standard Deviation 1.07
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 20: Erythema (Upper Limbs) (n=43, 39, 82)	-1.9 Units on a scale Standard Deviation 0.97	-1.9 Units on a scale Standard Deviation 1.26	-1.9 Units on a scale Standard Deviation 1.11
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 20: Erythema (Trunk) (n=43, 39, 82)	-2.2 Units on a scale Standard Deviation 1.04	-2.1 Units on a scale Standard Deviation 1.04	-2.1 Units on a scale Standard Deviation 1.04
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 20: Erythema (Lower Limbs) (n=43, 39, 82)	-2.1 Units on a scale Standard Deviation 1.04	-2.1 Units on a scale Standard Deviation 1.09	-2.1 Units on a scale Standard Deviation 1.05
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 20: Induration (Head/Neck) (n=43, 39, 82)	-1.6 Units on a scale Standard Deviation 1.00	-1.5 Units on a scale Standard Deviation 1.12	-1.6 Units on a scale Standard Deviation 1.06
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 20: Induration (Upper Limbs) (n=43, 39, 82)	-1.9 Units on a scale Standard Deviation 0.97	-1.7 Units on a scale Standard Deviation 1.14	-1.8 Units on a scale Standard Deviation 1.05
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 20: Induration (Trunk) (n=43, 39, 82)	-2.1 Units on a scale Standard Deviation 1.01	-1.9 Units on a scale Standard Deviation 1.07	-2.0 Units on a scale Standard Deviation 1.04
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 20: Induration (Lower Limbs) (n=43, 39, 82)	-2.2 Units on a scale Standard Deviation 0.95	-2.0 Units on a scale Standard Deviation 1.06	-2.1 Units on a scale Standard Deviation 1.00
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 20: Scaling (Head/Neck) (n=43, 39, 82)	-1.7 Units on a scale Standard Deviation 0.94	-1.5 Units on a scale Standard Deviation 1.05	-1.6 Units on a scale Standard Deviation 0.99
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 20: Scaling (Upper Limbs) (n=43, 39, 82)	-1.5 Units on a scale Standard Deviation 0.96	-1.6 Units on a scale Standard Deviation 1.14	-1.5 Units on a scale Standard Deviation 1.04
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 20: Scaling (Trunk) (n=43, 39, 82)	-1.7 Units on a scale Standard Deviation 0.93	-1.8 Units on a scale Standard Deviation 1.05	-1.8 Units on a scale Standard Deviation 0.99
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 20: Scaling (Lower Limbs) (n=43, 39, 82)	-1.7 Units on a scale Standard Deviation 0.92	-1.8 Units on a scale Standard Deviation 1.16	-1.8 Units on a scale Standard Deviation 1.04
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 28: Erythema (Head/Neck) (n=43, 39, 82)	-1.8 Units on a scale Standard Deviation 1.11	-1.6 Units on a scale Standard Deviation 0.81	-1.7 Units on a scale Standard Deviation 0.98
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 28: Erythema (Upper Limbs) (n=43, 39, 82)	-2.1 Units on a scale Standard Deviation 1.09	-1.8 Units on a scale Standard Deviation 1.07	-2.0 Units on a scale Standard Deviation 1.08
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 28: Erythema (Trunk) (n=43, 39, 82)	-2.1 Units on a scale Standard Deviation 1.13	-2.0 Units on a scale Standard Deviation 0.99	-2.1 Units on a scale Standard Deviation 1.06
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 28: Erythema (Lower Limbs) (n=43, 39, 82)	-2.3 Units on a scale Standard Deviation 1.05	-1.9 Units on a scale Standard Deviation 0.99	-2.1 Units on a scale Standard Deviation 1.03
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 28: Induration (Head/Neck) (n=43, 39, 82)	-1.7 Units on a scale Standard Deviation 0.97	-1.6 Units on a scale Standard Deviation 0.99	-1.6 Units on a scale Standard Deviation 0.98
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 28: Induration (Upper Limbs) (n=43, 39, 82)	-2.0 Units on a scale Standard Deviation 1.12	-1.7 Units on a scale Standard Deviation 1.10	-1.9 Units on a scale Standard Deviation 1.12
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 28: Induration (Trunk) (n=43, 39, 82)	-2.0 Units on a scale Standard Deviation 1.12	-1.8 Units on a scale Standard Deviation 1.16	-1.9 Units on a scale Standard Deviation 1.14
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 28: Induration (Lower Limbs) (n=43, 39, 82)	-2.2 Units on a scale Standard Deviation 1.03	-1.8 Units on a scale Standard Deviation 1.14	-2.0 Units on a scale Standard Deviation 1.09
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 28: Scaling (Head/Neck) (n=43, 39, 82)	-1.7 Units on a scale Standard Deviation 1.01	-1.4 Units on a scale Standard Deviation 1.07	-1.6 Units on a scale Standard Deviation 1.04
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 28: Scaling (Upper Limbs) (n=43, 39, 82)	-1.8 Units on a scale Standard Deviation 1.05	-1.6 Units on a scale Standard Deviation 1.02	-1.7 Units on a scale Standard Deviation 1.03
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 28: Scaling (Lower Limbs) (n=43, 39, 82)	-1.8 Units on a scale Standard Deviation 1.09	-1.7 Units on a scale Standard Deviation 1.02	-1.7 Units on a scale Standard Deviation 1.05
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 40: Erythema (Head/Neck) (n=41, 38, 79)	-1.9 Units on a scale Standard Deviation 1.10	-1.7 Units on a scale Standard Deviation 0.90	-1.8 Units on a scale Standard Deviation 1.01
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 40: Erythema (Upper Limbs) (n=41, 38, 79)	-2.1 Units on a scale Standard Deviation 1.05	-1.9 Units on a scale Standard Deviation 1.06	-2.0 Units on a scale Standard Deviation 1.06
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 40: Erythema (Trunk) (n=41, 38, 79)	-2.1 Units on a scale Standard Deviation 1.04	-2.2 Units on a scale Standard Deviation 0.87	-2.2 Units on a scale Standard Deviation 0.95
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 40: Erythema (Lower Limbs) (n=41, 38, 79)	-2.4 Units on a scale Standard Deviation 1.05	-2.0 Units on a scale Standard Deviation 1.03	-2.2 Units on a scale Standard Deviation 1.05
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 40: Induration (Head/Neck) (n=41, 38, 79)	-1.7 Units on a scale Standard Deviation 1.05	-1.5 Units on a scale Standard Deviation 1.08	-1.6 Units on a scale Standard Deviation 1.07
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 40: Induration (Upper Limbs) (n=41, 38, 79)	-2.0 Units on a scale Standard Deviation 1.18	-1.8 Units on a scale Standard Deviation 0.98	-1.9 Units on a scale Standard Deviation 1.09
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 40: Induration (Trunk) (n=41, 38, 79)	-1.9 Units on a scale Standard Deviation 1.26	-2.1 Units on a scale Standard Deviation 0.93	-2.1 Units on a scale Standard Deviation 1.11
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 40: Induration (Lower Limbs) (n=41, 38, 79)	-2.2 Units on a scale Standard Deviation 1.14	-1.9 Units on a scale Standard Deviation 1.03	-2.1 Units on a scale Standard Deviation 1.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 40: Scaling (Head/Neck) (n=41, 38, 79)	-1.8 Units on a scale Standard Deviation 0.97	-1.4 Units on a scale Standard Deviation 1.00	-1.6 Units on a scale Standard Deviation 0.99
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 40: Scaling (Upper Limbs) (n=41, 38, 79)	-1.7 Units on a scale Standard Deviation 1.10	-1.8 Units on a scale Standard Deviation 0.94	-1.7 Units on a scale Standard Deviation 1.02
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 40: Scaling (Trunk) (n=41, 38, 79)	-1.7 Units on a scale Standard Deviation 0.93	-1.9 Units on a scale Standard Deviation 1.03	-1.8 Units on a scale Standard Deviation 0.98
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 40: Scaling (Lower Limbs) (n=41, 38, 79)	-1.9 Units on a scale Standard Deviation 1.11	-1.8 Units on a scale Standard Deviation 1.06	-1.8 Units on a scale Standard Deviation 1.08
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 52: Erythema (Head/Neck) (n=39, 32, 71)	-1.9 Units on a scale Standard Deviation 1.17	-1.6 Units on a scale Standard Deviation 1.24	-1.8 Units on a scale Standard Deviation 1.20
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 52: Erythema (Upper Limbs) (n=39, 32, 71)	-2.0 Units on a scale Standard Deviation 1.15	-2.0 Units on a scale Standard Deviation 0.90	-2.0 Units on a scale Standard Deviation 1.04
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 52: Erythema (Trunk) (n=39, 32, 71)	-2.2 Units on a scale Standard Deviation 1.01	-2.2 Units on a scale Standard Deviation 0.93	-2.2 Units on a scale Standard Deviation 0.97
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 52: Erythema (Lower Limbs) (n=39, 32, 71)	-2.1 Units on a scale Standard Deviation 1.11	-2.2 Units on a scale Standard Deviation 0.94	-2.1 Units on a scale Standard Deviation 1.03
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 52: Induration (Head/Neck) (n=39, 32, 71)	-1.7 Units on a scale Standard Deviation 1.06	-1.5 Units on a scale Standard Deviation 1.22	-1.6 Units on a scale Standard Deviation 1.13
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 52: Induration (Upper Limbs) (n=39, 32, 71)	-1.9 Units on a scale Standard Deviation 1.21	-2.0 Units on a scale Standard Deviation 0.97	-1.9 Units on a scale Standard Deviation 1.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 52: Induration (Trunk) (n=39, 32, 71)	-1.8 Units on a scale Standard Deviation 1.39	-2.1 Units on a scale Standard Deviation 1.03	-2.0 Units on a scale Standard Deviation 1.24
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 52: Induration (Lower Limbs) (n=39, 32, 71)	-2.0 Units on a scale Standard Deviation 1.29	-2.2 Units on a scale Standard Deviation 0.97	-2.1 Units on a scale Standard Deviation 1.15
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 52: Scaling (Upper Limbs) (n=39, 32, 71)	-1.6 Units on a scale Standard Deviation 1.02	-1.9 Units on a scale Standard Deviation 0.98	-1.7 Units on a scale Standard Deviation 1.01
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 52: Scaling (Trunk) (n=39, 32, 71)	-1.6 Units on a scale Standard Deviation 0.96	-1.9 Units on a scale Standard Deviation 1.01	-1.7 Units on a scale Standard Deviation 0.98
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 52: Scaling (Lower Limbs) (n=39, 32, 71)	-1.7 Units on a scale Standard Deviation 1.15	-2.0 Units on a scale Standard Deviation 1.03	-1.8 Units on a scale Standard Deviation 1.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 28: Scaling (Trunk) (n=43, 39, 82)	-1.7 Units on a scale Standard Deviation 0.99	-1.8 Units on a scale Standard Deviation 1.11	-1.7 Units on a scale Standard Deviation 1.05
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 8: Induration (Head/Neck) (n=43, 41, 84)	-1.3 Units on a scale Standard Deviation 0.91	-1.6 Units on a scale Standard Deviation 1.10	-1.4 Units on a scale Standard Deviation 1.01
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 8: Induration (Trunk) (n=43, 41, 84)	-1.6 Units on a scale Standard Deviation 0.98	-1.7 Units on a scale Standard Deviation 1.03	-1.7 Units on a scale Standard Deviation 1.00
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 8: Induration (Lower Limbs) (n=43, 41, 84)	-1.6 Units on a scale Standard Deviation 0.91	-1.7 Units on a scale Standard Deviation 0.98	-1.7 Units on a scale Standard Deviation 0.94
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 8: Scaling (Upper Limbs) (n=43, 41, 84)	-1.3 Units on a scale Standard Deviation 0.80	-1.6 Units on a scale Standard Deviation 0.86	-1.5 Units on a scale Standard Deviation 0.84
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 8: Scaling (Trunk) (n=43, 41, 84)	-1.4 Units on a scale Standard Deviation 0.82	-1.8 Units on a scale Standard Deviation 1.00	-1.6 Units on a scale Standard Deviation 0.93
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 8: Scaling (Lower Limbs) (n=43, 41, 84)	-1.3 Units on a scale Standard Deviation 0.82	-1.8 Units on a scale Standard Deviation 0.88	-1.5 Units on a scale Standard Deviation 0.88
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 12: Erythema (Head/Neck) (n=43, 41, 84)	-1.7 Units on a scale Standard Deviation 1.10	-1.7 Units on a scale Standard Deviation 0.98	-1.7 Units on a scale Standard Deviation 1.04
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 12: Erythema (Upper Limbs) (n=43, 41, 84)	-1.9 Units on a scale Standard Deviation 0.99	-1.8 Units on a scale Standard Deviation 1.13	-1.8 Units on a scale Standard Deviation 1.05
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 12: Erythema (Trunk) (n=43, 41, 84)	-2.1 Units on a scale Standard Deviation 1.08	-2.0 Units on a scale Standard Deviation 0.95	-2.0 Units on a scale Standard Deviation 1.01
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 12: Erythema (Lower Limbs) (n=43, 41, 84)	-1.9 Units on a scale Standard Deviation 0.92	-1.9 Units on a scale Standard Deviation 0.94	-1.9 Units on a scale Standard Deviation 0.92
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 12: Induration (Head/Neck) (n=43, 41, 84)	-1.5 Units on a scale Standard Deviation 0.94	-1.6 Units on a scale Standard Deviation 1.12	-1.6 Units on a scale Standard Deviation 1.02
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 12: Scaling (Head/Neck) (n=43, 41, 84)	-1.7 Units on a scale Standard Deviation 0.92	-1.6 Units on a scale Standard Deviation 1.02	-1.6 Units on a scale Standard Deviation 0.96
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 12: Scaling (Upper Limbs) (n=43, 41, 84)	-1.4 Units on a scale Standard Deviation 0.91	-1.7 Units on a scale Standard Deviation 0.95	-1.6 Units on a scale Standard Deviation 0.94
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 12: Scaling (Trunk) (n=43, 41, 84)	-1.6 Units on a scale Standard Deviation 1.05	-1.9 Units on a scale Standard Deviation 1.00	-1.7 Units on a scale Standard Deviation 1.03
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 12: Scaling (Lower Limbs) (n=43, 41, 84)	-1.5 Units on a scale Standard Deviation 0.85	-1.9 Units on a scale Standard Deviation 1.00	-1.7 Units on a scale Standard Deviation 0.95
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 16: Erythema (Head/Neck) (n=43, 40, 83)	-1.7 Units on a scale Standard Deviation 1.14	-1.7 Units on a scale Standard Deviation 1.07	-1.7 Units on a scale Standard Deviation 1.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 16: Erythema (Upper Limbs) (n=43, 40, 83)	-1.9 Units on a scale Standard Deviation 1.13	-1.9 Units on a scale Standard Deviation 1.12	-1.9 Units on a scale Standard Deviation 1.12
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 16: Induration (Head/Neck) (n=43, 40, 83)	-1.5 Units on a scale Standard Deviation 0.96	-1.6 Units on a scale Standard Deviation 1.17	-1.6 Units on a scale Standard Deviation 1.06
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 16: Scaling (Head/Neck) (n=43, 40, 83)	-1.6 Units on a scale Standard Deviation 0.95	-1.6 Units on a scale Standard Deviation 1.08	-1.6 Units on a scale Standard Deviation 1.01
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 16: Induration (Upper Limbs) (n=43, 40, 83)	-1.8 Units on a scale Standard Deviation 0.96	-1.8 Units on a scale Standard Deviation 1.01	-1.8 Units on a scale Standard Deviation 0.98
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 16: Induration (Trunk) (n=43, 40, 83)	-2.1 Units on a scale Standard Deviation 1.01	-2.0 Units on a scale Standard Deviation 1.01	-2.0 Units on a scale Standard Deviation 1.01
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 16: Induration (Lower Limbs) (n=43, 40, 83)	-2.1 Units on a scale Standard Deviation 0.95	-2.0 Units on a scale Standard Deviation 1.08	-2.0 Units on a scale Standard Deviation 1.01
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 2: Erythema (Head/Neck)	-0.5 Units on a scale Standard Deviation 0.83	-0.9 Units on a scale Standard Deviation 0.82	-0.7 Units on a scale Standard Deviation 0.84
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 2: Erythema (Upper Limbs)	-0.5 Units on a scale Standard Deviation 0.67	-0.8 Units on a scale Standard Deviation 0.72	-0.6 Units on a scale Standard Deviation 0.70
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 2: Erythema (Trunk)	-0.6 Units on a scale Standard Deviation 0.67	-0.8 Units on a scale Standard Deviation 0.69	-0.7 Units on a scale Standard Deviation 0.69
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 2: Erythema (Lower Limbs)	-0.7 Units on a scale Standard Deviation 0.69	-0.8 Units on a scale Standard Deviation 0.71	-0.7 Units on a scale Standard Deviation 0.70
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 2: Induration (Head/Neck)	-0.4 Units on a scale Standard Deviation 0.70	-0.8 Units on a scale Standard Deviation 0.89	-0.6 Units on a scale Standard Deviation 0.82
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 2: Induration (Upper Limbs)	-0.5 Units on a scale Standard Deviation 0.63	-0.6 Units on a scale Standard Deviation 0.75	-0.6 Units on a scale Standard Deviation 0.69
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 2: Induration (Trunk)	-0.5 Units on a scale Standard Deviation 0.63	-0.7 Units on a scale Standard Deviation 0.59	-0.6 Units on a scale Standard Deviation 0.62
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 2: Induration (Lower Limbs)	-0.5 Units on a scale Standard Deviation 0.67	-0.7 Units on a scale Standard Deviation 0.71	-0.6 Units on a scale Standard Deviation 0.69
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 2: Scaling (Head/Neck)	-0.4 Units on a scale Standard Deviation 0.66	-0.9 Units on a scale Standard Deviation 0.91	-0.7 Units on a scale Standard Deviation 0.83
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 2: Scaling (Upper Limbs)	-0.4 Units on a scale Standard Deviation 0.59	-0.8 Units on a scale Standard Deviation 0.74	-0.6 Units on a scale Standard Deviation 0.69
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 2: Scaling (Trunk)	-0.3 Units on a scale Standard Deviation 0.57	-0.8 Units on a scale Standard Deviation 0.76	-0.6 Units on a scale Standard Deviation 0.71
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 2: Scaling (Lower Limbs)	-0.4 Units on a scale Standard Deviation 0.70	-0.7 Units on a scale Standard Deviation 0.73	-0.6 Units on a scale Standard Deviation 0.73
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 4: Erythema (Head/Neck)	-0.8 Units on a scale Standard Deviation 1.02	-1.3 Units on a scale Standard Deviation 0.99	-1.0 Units on a scale Standard Deviation 1.02
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 4: Erythema (Upper Limbs)	-1.1 Units on a scale Standard Deviation 0.81	-1.2 Units on a scale Standard Deviation 0.94	-1.1 Units on a scale Standard Deviation 0.87
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 4: Erythema (Trunk)	-1.0 Units on a scale Standard Deviation 0.64	-1.3 Units on a scale Standard Deviation 0.79	-1.1 Units on a scale Standard Deviation 0.72
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 4: Erythema (Lower Limbs)	-1.1 Units on a scale Standard Deviation 0.91	-1.2 Units on a scale Standard Deviation 0.79	-1.2 Units on a scale Standard Deviation 0.85
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score Week 4: Induration (Trunk)	-0.9 Units on a scale Standard Deviation 0.80	-1.3 Units on a scale Standard Deviation 0.82	-1.1 Units on a scale Standard Deviation 0.83

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 20, 28, 40, 52

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' Week 2	7.0 Percentage of participants	15.9 Percentage of participants	11.5 Percentage of participants
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' Week 4	30.2 Percentage of participants	38.6 Percentage of participants	34.5 Percentage of participants
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' Week 8	58.1 Percentage of participants	61.4 Percentage of participants	59.8 Percentage of participants
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' Week 12	72.1 Percentage of participants	75.0 Percentage of participants	73.6 Percentage of participants
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' Week 28	67.4 Percentage of participants	54.5 Percentage of participants	60.9 Percentage of participants
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' Week 40	67.4 Percentage of participants	54.5 Percentage of participants	60.9 Percentage of participants
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' Week 52	58.1 Percentage of participants	56.8 Percentage of participants	57.5 Percentage of participants
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' Week 20	72.1 Percentage of participants	59.1 Percentage of participants	65.5 Percentage of participants

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 2: Clear	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 2: Mild	39.5 Percentage of participants	43.2 Percentage of participants	41.4 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 2: Moderate	46.5 Percentage of participants	34.1 Percentage of participants	40.2 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 2: Severe	7.0 Percentage of participants	6.8 Percentage of participants	6.9 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 4: Clear	0 Percentage of participants	11.4 Percentage of participants	5.7 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 4: Mild	44.2 Percentage of participants	40.9 Percentage of participants	42.5 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 4: Moderate	18.6 Percentage of participants	20.5 Percentage of participants	19.5 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 4: Severe	7.0 Percentage of participants	0 Percentage of participants	3.4 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 8: Moderate (n=43, 41, 84)	14.0 Percentage of participants	9.8 Percentage of participants	11.9 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 8: Severe (n=43, 41, 84)	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 12: Clear (n=43, 41, 84)	14.0 Percentage of participants	36.6 Percentage of participants	25.0 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 12: Almost Clear (n=43, 41, 84)	58.1 Percentage of participants	43.9 Percentage of participants	51.2 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 12: Mild (n=43, 41, 84)	20.9 Percentage of participants	9.8 Percentage of participants	15.5 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 12: Moderate (n=43, 41, 84)	7.0 Percentage of participants	9.8 Percentage of participants	8.3 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 12: Severe (n=43, 41, 84)	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 16: Clear (n=43, 40, 83)	27.9 Percentage of participants	40.0 Percentage of participants	33.7 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 16: Almost Clear (n=43, 40, 83)	39.5 Percentage of participants	35.0 Percentage of participants	37.3 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 28: Clear (n=43, 39, 82)	37.2 Percentage of participants	33.3 Percentage of participants	35.4 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 28: Almost Clear (n=43, 39, 82)	30.2 Percentage of participants	28.2 Percentage of participants	29.3 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 40: Mild (n=41, 38, 79)	24.4 Percentage of participants	28.9 Percentage of participants	26.6 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 52: Severe (n=39, 32, 71)	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 8: Almost Clear (n=43, 41, 84)	51.2 Percentage of participants	39.0 Percentage of participants	45.2 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 8: Mild (n=43, 41, 84)	27.9 Percentage of participants	24.4 Percentage of participants	26.2 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 16: Mild (n=43, 40, 83)	25.6 Percentage of participants	17.5 Percentage of participants	21.7 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 16: Moderate (n=43, 40, 83)	7.0 Percentage of participants	5.0 Percentage of participants	6.0 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 16: Severe (n=43, 40, 83)	0 Percentage of participants	2.5 Percentage of participants	1.2 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 20: Clear (n=43, 39, 82)	27.9 Percentage of participants	38.5 Percentage of participants	32.9 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 20: Almost Clear (n=43, 39, 82)	44.2 Percentage of participants	28.2 Percentage of participants	36.6 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 20: Mild (n=43, 39, 82)	18.6 Percentage of participants	25.6 Percentage of participants	22.0 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 20: Moderate (n=43, 39, 82)	9.3 Percentage of participants	7.7 Percentage of participants	8.5 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 20: Severe(n=43, 39, 82)	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 28: Mild (n=43, 39, 82)	27.9 Percentage of participants	30.8 Percentage of participants	29.3 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 28: Moderate (n=43, 39, 82)	4.7 Percentage of participants	7.7 Percentage of participants	6.1 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 28: Severe (n=43, 39, 82)	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 40: Clear (n=41, 38, 79)	43.9 Percentage of participants	34.2 Percentage of participants	39.2 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 40: Almost Clear (n=41, 38, 79)	26.8 Percentage of participants	28.9 Percentage of participants	27.8 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 40: Moderate (n=41, 38, 79)	4.9 Percentage of participants	7.9 Percentage of participants	6.3 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 40: Severe (n=41, 38, 79)	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 52: Clear (n=39, 32, 71)	41.0 Percentage of participants	43.8 Percentage of participants	42.3 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 52: Almost Clear (n=39, 32, 71)	23.1 Percentage of participants	34.4 Percentage of participants	28.2 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 52: Mild (n=39, 32, 71)	30.8 Percentage of participants	18.8 Percentage of participants	25.4 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 52: Moderate (n=39, 32, 71)	5.1 Percentage of participants	3.1 Percentage of participants	4.2 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 2: Almost Clear	7.0 Percentage of participants	15.9 Percentage of participants	11.5 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 4: Almost Clear	30.2 Percentage of participants	27.3 Percentage of participants	28.7 Percentage of participants
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category Week 8: Clear (n=43, 41, 84)	7.0 Percentage of participants	26.8 Percentage of participants	16.7 Percentage of participants

SECONDARY outcome

Timeframe: Week 20, 28, 40, 52

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among participants achieving PASI75 response at Week 16 is reported.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=28 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=35 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=63 Participants (=sum across Arm/Groups)
Percentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16 Week 20	96.3 Percentage of participants	87.5 Percentage of participants	91.5 Percentage of participants
Percentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16 Week 28	92.6 Percentage of participants	78.1 Percentage of participants	84.7 Percentage of participants
Percentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16 Week 40	81.5 Percentage of participants	71.9 Percentage of participants	76.3 Percentage of participants
Percentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16 Week 52	70.4 Percentage of participants	62.5 Percentage of participants	66.1 Percentage of participants

SECONDARY outcome

Timeframe: Week 20, 28, 40, 52

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=30 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=31 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=61 Participants (=sum across Arm/Groups)
Percentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' Week 20	100 Percentage of participants	83.3 Percentage of participants	91.5 Percentage of participants
Percentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' Week 28	93.1 Percentage of participants	73.3 Percentage of participants	83.1 Percentage of participants
Percentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' Week 40	82.8 Percentage of participants	66.7 Percentage of participants	74.6 Percentage of participants
Percentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' Week 52	65.5 Percentage of participants	60.0 Percentage of participants	62.7 Percentage of participants

SECONDARY outcome

Timeframe: Week 8, 16, 20, 28, 40, 52

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=32 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=30 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=62 Participants (=sum across Arm/Groups)
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score Week 28 (n=32, 27, 59)	-21.1 Units on a scale Standard Deviation 15.83	-16.4 Units on a scale Standard Deviation 15.27	-18.9 Units on a scale Standard Deviation 15.62
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score Week 8 (n=32, 28, 60)	-3.3 Units on a scale Standard Deviation 9.63	-1.8 Units on a scale Standard Deviation 7.72	-2.6 Units on a scale Standard Deviation 8.75
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score Week 16 (n=32, 28, 60)	-11.2 Units on a scale Standard Deviation 15.27	-9.4 Units on a scale Standard Deviation 12.66	-10.4 Units on a scale Standard Deviation 14.02
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score Week 20 (n=32, 27, 59)	-15.0 Units on a scale Standard Deviation 15.29	-14.1 Units on a scale Standard Deviation 13.03	-14.6 Units on a scale Standard Deviation 14.18
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score Week 40 (n=31, 26, 57)	-22.2 Units on a scale Standard Deviation 16.18	-16.2 Units on a scale Standard Deviation 14.13	-19.5 Units on a scale Standard Deviation 15.45
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score Week 52 (n=30, 22, 52)	-20.6 Units on a scale Standard Deviation 15.16	-16.2 Units on a scale Standard Deviation 15.62	-18.7 Units on a scale Standard Deviation 15.36

SECONDARY outcome

Timeframe: Baseline, Week 8, 16, 20, 28, 40, 52

Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=32 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=30 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=62 Participants (=sum across Arm/Groups)
Number of Affected Nails Baseline	7.94 nails Standard Deviation 2.82	7.13 nails Standard Deviation 3.07	7.55 nails Standard Deviation 2.95
Number of Affected Nails Week 8 (n=32, 28, 60)	7.66 nails Standard Deviation 3.17	7.11 nails Standard Deviation 3.02	7.40 nails Standard Deviation 3.09
Number of Affected Nails Week 16 (n=32, 28, 60)	6.91 nails Standard Deviation 3.43	5.75 nails Standard Deviation 3.56	6.37 nails Standard Deviation 3.51
Number of Affected Nails Week 20 (n=32, 27, 59)	6.16 nails Standard Deviation 3.60	4.59 nails Standard Deviation 4.02	5.44 nails Standard Deviation 3.85
Number of Affected Nails Week 28 (n=32, 27, 59)	4.53 nails Standard Deviation 3.87	3.59 nails Standard Deviation 3.96	4.10 nails Standard Deviation 3.91
Number of Affected Nails Week 40 (n=31, 26, 57)	3.32 nails Standard Deviation 3.94	3.77 nails Standard Deviation 3.81	3.53 nails Standard Deviation 3.85
Number of Affected Nails Week 52 (n=30, 22, 52)	3.73 nails Standard Deviation 4.25	2.50 nails Standard Deviation 3.07	3.21 nails Standard Deviation 3.81

SECONDARY outcome

Timeframe: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52

ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Itch Severity Item (ISI) Score Week 2	5.19 Units on a scale Standard Deviation 2.797	3.30 Units on a scale Standard Deviation 2.530	4.23 Units on a scale Standard Deviation 2.815
Itch Severity Item (ISI) Score Week 4	3.65 Units on a scale Standard Deviation 2.379	2.27 Units on a scale Standard Deviation 2.472	2.95 Units on a scale Standard Deviation 2.510
Itch Severity Item (ISI) Score Week 8 (n=43, 41, 84)	2.26 Units on a scale Standard Deviation 2.381	1.22 Units on a scale Standard Deviation 1.739	1.75 Units on a scale Standard Deviation 2.145
Itch Severity Item (ISI) Score Week 12 (n=43, 41, 84)	1.77 Units on a scale Standard Deviation 2.379	1.20 Units on a scale Standard Deviation 1.833	1.49 Units on a scale Standard Deviation 2.137
Itch Severity Item (ISI) Score Week 20 (n=43, 39, 82)	0.95 Units on a scale Standard Deviation 1.618	1.28 Units on a scale Standard Deviation 1.589	1.11 Units on a scale Standard Deviation 1.603
Itch Severity Item (ISI) Score Week 40 (n=41, 38, 79)	0.90 Units on a scale Standard Deviation 1.814	1.13 Units on a scale Standard Deviation 1.848	1.01 Units on a scale Standard Deviation 1.822
Itch Severity Item (ISI) Score Baseline	6.16 Units on a scale Standard Deviation 2.669	5.32 Units on a scale Standard Deviation 2.967	5.74 Units on a scale Standard Deviation 2.839
Itch Severity Item (ISI) Score Week 16 (n=43, 40, 83)	1.67 Units on a scale Standard Deviation 2.378	0.90 Units on a scale Standard Deviation 1.257	1.30 Units on a scale Standard Deviation 1.949
Itch Severity Item (ISI) Score Week 28 (n=43, 39, 82)	1.12 Units on a scale Standard Deviation 1.651	1.62 Units on a scale Standard Deviation 2.196	1.35 Units on a scale Standard Deviation 1.933
Itch Severity Item (ISI) Score Week 52 (n=39, 32, 71)	1.15 Units on a scale Standard Deviation 2.084	0.91 Units on a scale Standard Deviation 1.329	1.04 Units on a scale Standard Deviation 1.776

SECONDARY outcome

Timeframe: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52

The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Dermatology Life Quality Index (DLQI) Score Week 4 (n=43, 43, 86)	5.9 Units on a scale Standard Deviation 5.07	4.2 Units on a scale Standard Deviation 4.63	5.1 Units on a scale Standard Deviation 4.90
Dermatology Life Quality Index (DLQI) Score Week 20 (n=43, 39, 82)	1.9 Units on a scale Standard Deviation 3.13	1.8 Units on a scale Standard Deviation 2.54	1.9 Units on a scale Standard Deviation 2.84
Dermatology Life Quality Index (DLQI) Score Week 28 (n=43, 39, 82)	1.7 Units on a scale Standard Deviation 2.66	2.9 Units on a scale Standard Deviation 3.68	2.3 Units on a scale Standard Deviation 3.23
Dermatology Life Quality Index (DLQI) Score Baseline	11.3 Units on a scale Standard Deviation 6.25	8.6 Units on a scale Standard Deviation 5.91	9.9 Units on a scale Standard Deviation 6.19
Dermatology Life Quality Index (DLQI) Score Week 2	7.8 Units on a scale Standard Deviation 5.20	5.8 Units on a scale Standard Deviation 5.32	6.8 Units on a scale Standard Deviation 5.32
Dermatology Life Quality Index (DLQI) Score Week 8 (n=43, 41, 84)	4.0 Units on a scale Standard Deviation 3.95	2.8 Units on a scale Standard Deviation 3.30	3.4 Units on a scale Standard Deviation 3.67
Dermatology Life Quality Index (DLQI) Score Week 12 (n=43, 41, 84)	2.6 Units on a scale Standard Deviation 2.86	1.8 Units on a scale Standard Deviation 2.68	2.2 Units on a scale Standard Deviation 2.79
Dermatology Life Quality Index (DLQI) Score Week 16 (n=43, 40, 83)	2.2 Units on a scale Standard Deviation 3.04	1.9 Units on a scale Standard Deviation 2.73	2.1 Units on a scale Standard Deviation 2.88
Dermatology Life Quality Index (DLQI) Score Week 40 (n=41, 38, 79)	1.8 Units on a scale Standard Deviation 2.81	2.3 Units on a scale Standard Deviation 4.11	2.0 Units on a scale Standard Deviation 3.48
Dermatology Life Quality Index (DLQI) Score Week 52 (n=39, 32, 71)	1.6 Units on a scale Standard Deviation 2.42	2.2 Units on a scale Standard Deviation 4.00	1.9 Units on a scale Standard Deviation 3.22

SECONDARY outcome

Timeframe: Week (W) 16, 28, 52

36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W16: Bodily Pain Domain (n=43, 40, 83)	11.808 Units on a scale Standard Deviation 13.8431	10.663 Units on a scale Standard Deviation 12.2936	11.256 Units on a scale Standard Deviation 13.0524
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W52: Social Function Domain (n=39, 32, 71)	8.411 Units on a scale Standard Deviation 9.4598	8.402 Units on a scale Standard Deviation 9.2577	8.407 Units on a scale Standard Deviation 9.3024
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W52: Bodily Pain Domain (n=39, 32, 71)	12.335 Units on a scale Standard Deviation 12.1413	10.673 Units on a scale Standard Deviation 9.7128	11.586 Units on a scale Standard Deviation 11.0678
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W52: General Health Domain (n=39, 32, 71)	2.758 Units on a scale Standard Deviation 6.0866	4.888 Units on a scale Standard Deviation 6.8235	3.718 Units on a scale Standard Deviation 6.4707
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W52: Vitality Domain (n=39, 32, 71)	4.068 Units on a scale Standard Deviation 10.5612	5.052 Units on a scale Standard Deviation 8.5160	4.511 Units on a scale Standard Deviation 9.6390
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W52: Role-Emotional Domain (n=39, 32, 71)	8.445 Units on a scale Standard Deviation 11.0018	5.915 Units on a scale Standard Deviation 10.3091	7.305 Units on a scale Standard Deviation 10.6949
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W52: Mental Health Domain (n=39, 32, 71)	7.317 Units on a scale Standard Deviation 11.6243	6.926 Units on a scale Standard Deviation 12.6861	7.141 Units on a scale Standard Deviation 12.0276
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W16: Physical Functioning Domain (n=43, 40, 83)	1.951 Units on a scale Standard Deviation 5.1880	4.809 Units on a scale Standard Deviation 9.1822	3.329 Units on a scale Standard Deviation 7.4800
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W16: Role-Physical Domain (n=43, 40, 83)	6.160 Units on a scale Standard Deviation 9.3615	5.130 Units on a scale Standard Deviation 11.1600	5.664 Units on a scale Standard Deviation 10.2172
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W16: General Health Domain (n=43, 40, 83)	2.392 Units on a scale Standard Deviation 7.0933	4.333 Units on a scale Standard Deviation 7.0145	3.328 Units on a scale Standard Deviation 7.0799
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W16: Vitality Domain (n=43, 40, 83)	4.664 Units on a scale Standard Deviation 9.5406	3.517 Units on a scale Standard Deviation 11.4421	4.112 Units on a scale Standard Deviation 10.4509
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W16: Social Function Domain (n=43, 40, 83)	7.629 Units on a scale Standard Deviation 9.9734	7.932 Units on a scale Standard Deviation 8.8645	7.775 Units on a scale Standard Deviation 9.3992
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W16: Role-Emotional Domain (n=43, 40, 83)	7.219 Units on a scale Standard Deviation 11.5898	5.584 Units on a scale Standard Deviation 11.5654	6.431 Units on a scale Standard Deviation 11.5365
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W16: Mental Health Domain (n=43, 40, 83)	5.928 Units on a scale Standard Deviation 12.8757	5.125 Units on a scale Standard Deviation 13.3613	5.541 Units on a scale Standard Deviation 13.0378
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W28: Physical Functioning Domain (n=43, 39, 82)	1.571 Units on a scale Standard Deviation 6.3446	4.303 Units on a scale Standard Deviation 10.3695	2.870 Units on a scale Standard Deviation 8.5558
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W28: Role-Physical Domain (n=43, 39, 82)	5.882 Units on a scale Standard Deviation 10.6375	5.017 Units on a scale Standard Deviation 11.4671	5.471 Units on a scale Standard Deviation 10.9795
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W28: Bodily Pain Domain (n=43, 39, 82)	10.113 Units on a scale Standard Deviation 15.9485	8.394 Units on a scale Standard Deviation 12.5405	9.295 Units on a scale Standard Deviation 14.3670
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W28: General Health Domain (n=43, 39, 82)	2.644 Units on a scale Standard Deviation 5.9230	3.517 Units on a scale Standard Deviation 7.1375	3.059 Units on a scale Standard Deviation 6.5025
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W28: Vitality Domain (n=43, 39, 82)	4.038 Units on a scale Standard Deviation 10.0116	3.608 Units on a scale Standard Deviation 10.0742	3.833 Units on a scale Standard Deviation 9.9815
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W28: Social Function Domain (n=43, 39, 82)	6.628 Units on a scale Standard Deviation 11.3068	6.205 Units on a scale Standard Deviation 10.4347	6.427 Units on a scale Standard Deviation 10.8358
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W28: Role-Emotional Domain (n=43, 39, 82)	7.395 Units on a scale Standard Deviation 11.8846	6.310 Units on a scale Standard Deviation 12.9504	6.879 Units on a scale Standard Deviation 12.3375
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W28: Mental Health Domain (n=43, 39, 82)	6.701 Units on a scale Standard Deviation 12.4375	5.328 Units on a scale Standard Deviation 12.8129	6.048 Units on a scale Standard Deviation 12.5580
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W52: Physical Functioning Domain (n=39,32,71)	2.151 Units on a scale Standard Deviation 5.6134	3.773 Units on a scale Standard Deviation 7.3533	2.882 Units on a scale Standard Deviation 6.4585
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score W52: Role-Physical Domain (n=39, 32, 71)	6.669 Units on a scale Standard Deviation 10.0520	4.623 Units on a scale Standard Deviation 9.7340	5.747 Units on a scale Standard Deviation 9.8926

SECONDARY outcome

Timeframe: Week 16, 28, 52

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score Week 16: Physical Health Score (n=43, 40, 83)	4.719 Units on a scale Standard Deviation 6.6806	6.146 Units on a scale Standard Deviation 8.5192	5.407 Units on a scale Standard Deviation 7.6087
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score Week 16: Mental Health Score (n=43, 40, 83)	6.767 Units on a scale Standard Deviation 11.0945	5.029 Units on a scale Standard Deviation 11.4967	5.929 Units on a scale Standard Deviation 11.2548
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score Week 28: Physical Health Score (n=43, 39, 82)	3.770 Units on a scale Standard Deviation 7.7829	4.799 Units on a scale Standard Deviation 8.8893	4.259 Units on a scale Standard Deviation 8.2914
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score Week 28: Mental Health Score (n=43, 39, 82)	7.085 Units on a scale Standard Deviation 11.3660	5.364 Units on a scale Standard Deviation 10.9089	6.266 Units on a scale Standard Deviation 11.1159
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score Week 52: Physical Health Score (n=39, 32, 71)	4.676 Units on a scale Standard Deviation 5.7405	5.250 Units on a scale Standard Deviation 5.7614	4.935 Units on a scale Standard Deviation 5.7159
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score Week 52: Mental Health Score (n=39, 32, 71)	7.878 Units on a scale Standard Deviation 10.1983	6.826 Units on a scale Standard Deviation 10.5988	7.404 Units on a scale Standard Deviation 10.3192

SECONDARY outcome

Timeframe: Baseline (BL), Week (W) 4, 16, 28, 52

WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 \[no loss\] to 100 \[complete loss of work\]).

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Work Limitation Questionnaire (WLQ) W28:Mental/Interpersonal Demands Scale(n=33,35,68)	16.84 Units on a scale Standard Deviation 28.242	16.39 Units on a scale Standard Deviation 27.736	16.61 Units on a scale Standard Deviation 27.774
Work Limitation Questionnaire (WLQ) BL: Mental/Interpersonal Demands Scale(n=34,38,72)	28.61 Units on a scale Standard Deviation 29.012	31.52 Units on a scale Standard Deviation 30.930	30.15 Units on a scale Standard Deviation 29.865
Work Limitation Questionnaire (WLQ) BL: Output Demands scale (n=33, 37, 70)	22.61 Units on a scale Standard Deviation 26.832	30.27 Units on a scale Standard Deviation 35.295	26.66 Units on a scale Standard Deviation 31.602
Work Limitation Questionnaire (WLQ) BL: WLQ Index Score (n=34, 38, 72)	9.55 Units on a scale Standard Deviation 6.716	10.74 Units on a scale Standard Deviation 8.045	10.18 Units on a scale Standard Deviation 7.420
Work Limitation Questionnaire (WLQ) BL: Time Management scale (n=34, 37, 71)	44.49 Units on a scale Standard Deviation 37.783	42.36 Units on a scale Standard Deviation 33.716	43.38 Units on a scale Standard Deviation 35.479
Work Limitation Questionnaire (WLQ) BL: Physical Demands scale (n=33, 35, 68)	66.67 Units on a scale Standard Deviation 33.522	78.40 Units on a scale Standard Deviation 31.122	72.71 Units on a scale Standard Deviation 32.606
Work Limitation Questionnaire (WLQ) W4: Time Management scale (n=31, 36, 67)	35.32 Units on a scale Standard Deviation 42.425	31.39 Units on a scale Standard Deviation 36.715	33.21 Units on a scale Standard Deviation 39.203
Work Limitation Questionnaire (WLQ) W4: Physical Demands scale (n=29, 36, 65)	77.16 Units on a scale Standard Deviation 33.013	83.59 Units on a scale Standard Deviation 29.593	80.72 Units on a scale Standard Deviation 31.083
Work Limitation Questionnaire (WLQ) W4:Mental/Interpersonal Demands Scale(n=32,36,68)	17.94 Units on a scale Standard Deviation 26.979	23.39 Units on a scale Standard Deviation 32.878	20.82 Units on a scale Standard Deviation 30.149
Work Limitation Questionnaire (WLQ) W4: Output Demands scale (n=30, 36, 66)	13.50 Units on a scale Standard Deviation 21.978	20.14 Units on a scale Standard Deviation 33.306	17.12 Units on a scale Standard Deviation 28.704
Work Limitation Questionnaire (WLQ) W4: WLQ Index Score (n=32, 37, 69)	7.23 Units on a scale Standard Deviation 5.591	8.66 Units on a scale Standard Deviation 7.754	8.00 Units on a scale Standard Deviation 6.827
Work Limitation Questionnaire (WLQ) W16: Time Management scale (n=31, 35, 66)	35.07 Units on a scale Standard Deviation 38.894	33.29 Units on a scale Standard Deviation 39.182	34.12 Units on a scale Standard Deviation 38.756
Work Limitation Questionnaire (WLQ) W16: Physical Demands scale (n=30, 32, 62)	81.60 Units on a scale Standard Deviation 26.982	86.52 Units on a scale Standard Deviation 25.548	84.14 Units on a scale Standard Deviation 26.153
Work Limitation Questionnaire (WLQ) W16:Mental/Interpersonal Demands Scale(n=31,35,66)	13.33 Units on a scale Standard Deviation 21.038	20.28 Units on a scale Standard Deviation 33.419	17.01 Units on a scale Standard Deviation 28.296
Work Limitation Questionnaire (WLQ) W16: Output Demands scale (n=32, 33, 65)	11.88 Units on a scale Standard Deviation 20.111	19.55 Units on a scale Standard Deviation 32.485	15.77 Units on a scale Standard Deviation 27.175
Work Limitation Questionnaire (WLQ) W16: WLQ Index Score (n=32, 35, 67)	6.88 Units on a scale Standard Deviation 4.715	8.35 Units on a scale Standard Deviation 7.425	7.65 Units on a scale Standard Deviation 6.276
Work Limitation Questionnaire (WLQ) W28: Time Management scale (n=34, 34, 68)	38.68 Units on a scale Standard Deviation 40.100	29.78 Units on a scale Standard Deviation 39.092	34.23 Units on a scale Standard Deviation 39.557
Work Limitation Questionnaire (WLQ) W28: Physical Demands scale (n=32, 34, 66)	76.02 Units on a scale Standard Deviation 31.041	85.42 Units on a scale Standard Deviation 24.730	80.86 Units on a scale Standard Deviation 28.151
Work Limitation Questionnaire (WLQ) W28: Output Demands scale (n=33, 34, 67)	13.94 Units on a scale Standard Deviation 27.408	14.71 Units on a scale Standard Deviation 28.761	14.33 Units on a scale Standard Deviation 27.892
Work Limitation Questionnaire (WLQ) W28: WLQ Index Score (n=34, 36, 70)	7.43 Units on a scale Standard Deviation 6.493	7.26 Units on a scale Standard Deviation 6.829	7.34 Units on a scale Standard Deviation 6.620
Work Limitation Questionnaire (WLQ) W52: Time Management scale (n=31, 31, 62)	50.32 Units on a scale Standard Deviation 43.683	31.88 Units on a scale Standard Deviation 40.686	41.10 Units on a scale Standard Deviation 42.883
Work Limitation Questionnaire (WLQ) W52: Physical Demands scale (n=29, 29, 58)	78.16 Units on a scale Standard Deviation 30.205	89.74 Units on a scale Standard Deviation 24.410	83.95 Units on a scale Standard Deviation 27.838
Work Limitation Questionnaire (WLQ) W52:Mental/Interpersonal Demands Scale(n=30,30,60)	25.56 Units on a scale Standard Deviation 36.007	16.89 Units on a scale Standard Deviation 27.293	21.22 Units on a scale Standard Deviation 31.977
Work Limitation Questionnaire (WLQ) W52: Output Demands scale (n=30, 29, 59)	22.63 Units on a scale Standard Deviation 33.750	12.24 Units on a scale Standard Deviation 24.589	17.52 Units on a scale Standard Deviation 29.813
Work Limitation Questionnaire (WLQ) W52: WLQ Index Score (n=32, 31, 63)	9.44 Units on a scale Standard Deviation 8.127	7.34 Units on a scale Standard Deviation 6.429	8.41 Units on a scale Standard Deviation 7.358

SECONDARY outcome

Timeframe: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear \[no psoriasis\]; 1=almost clear; 2=mild; 3=moderate; 4=severe).

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=43 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=44 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=87 Participants (=sum across Arm/Groups)
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 40: Mild (n=41, 38, 79)	19.5 Percentage of participants	18.4 Percentage of participants	19.0 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Baseline: Clear	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Baseline: Almost Clear	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Baseline: Mild	0 Percentage of participants	2.3 Percentage of participants	1.1 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Baseline: Moderate	41.9 Percentage of participants	43.2 Percentage of participants	42.5 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Baseline: Severe	58.1 Percentage of participants	54.5 Percentage of participants	56.3 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 2: Clear	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 2: Almost Clear	2.3 Percentage of participants	0 Percentage of participants	1.1 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 2: Mild	2.3 Percentage of participants	29.5 Percentage of participants	16.1 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 2: Moderate	60.5 Percentage of participants	36.4 Percentage of participants	48.3 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 2: Severe	34.9 Percentage of participants	34.1 Percentage of participants	34.5 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 4: Clear (n=43, 43, 86)	0 Percentage of participants	2.3 Percentage of participants	1.2 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 4: Almost Clear (n=43, 43, 86)	4.7 Percentage of participants	9.3 Percentage of participants	7.0 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 4: Mild (n=43, 43, 86)	18.6 Percentage of participants	25.6 Percentage of participants	22.1 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 4: Moderate (n=43, 43, 86)	53.5 Percentage of participants	48.8 Percentage of participants	51.2 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 4: Severe (n=43, 43, 86)	23.3 Percentage of participants	14.0 Percentage of participants	18.6 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 8: Clear (n=43, 41, 84)	4.7 Percentage of participants	7.3 Percentage of participants	6.0 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 8: Almost Clear (n=43, 41, 84)	14.0 Percentage of participants	17.1 Percentage of participants	15.5 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 8: Mild (n=43, 41, 84)	32.6 Percentage of participants	34.1 Percentage of participants	33.3 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 8: Moderate (n=43, 41, 84)	39.5 Percentage of participants	34.1 Percentage of participants	36.9 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 8: Severe (n=43, 41, 84)	9.3 Percentage of participants	7.3 Percentage of participants	8.3 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 12: Clear (n=43, 41, 84)	2.3 Percentage of participants	7.3 Percentage of participants	4.8 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 12: Almost Clear (n=43, 41, 84)	20.9 Percentage of participants	26.8 Percentage of participants	23.8 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 12: Mild (n=43, 41, 84)	34.9 Percentage of participants	41.5 Percentage of participants	38.1 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 12: Moderate (n=43, 41, 84)	34.9 Percentage of participants	17.1 Percentage of participants	26.2 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 12: Severe (n=43, 41, 84)	7.0 Percentage of participants	7.3 Percentage of participants	7.1 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 16: Clear (n=43, 40, 83)	4.7 Percentage of participants	10.0 Percentage of participants	7.2 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 16: Almost Clear (n=43, 40, 83)	32.6 Percentage of participants	22.5 Percentage of participants	27.7 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 16: Mild (n=43, 40, 83)	23.3 Percentage of participants	35.0 Percentage of participants	28.9 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 16: Moderate (n=43, 40, 83)	32.6 Percentage of participants	22.5 Percentage of participants	27.7 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 16: Severe (n=43, 40, 83)	7.0 Percentage of participants	10.0 Percentage of participants	8.4 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 20: Clear (n=43, 39, 82)	7.0 Percentage of participants	12.8 Percentage of participants	9.8 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 20: Almost Clear (n=43, 39, 82)	37.2 Percentage of participants	23.1 Percentage of participants	30.5 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 20: Mild (n=43, 39, 82)	25.6 Percentage of participants	33.3 Percentage of participants	29.3 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 20: Moderate (n=43, 39, 82)	23.3 Percentage of participants	25.6 Percentage of participants	24.4 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 20: Severe (n=43, 39, 82)	7.0 Percentage of participants	5.1 Percentage of participants	6.1 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 28: Clear (n=43, 39, 82)	11.6 Percentage of participants	5.1 Percentage of participants	8.5 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 28: Almost Clear (n=43, 39, 82)	37.2 Percentage of participants	35.9 Percentage of participants	36.6 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 28: Mild (n=43, 39, 82)	23.3 Percentage of participants	20.5 Percentage of participants	22.0 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 28: Moderate (n=43, 39, 82)	20.9 Percentage of participants	33.3 Percentage of participants	26.8 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 28: Severe (n=43, 39, 82)	7.0 Percentage of participants	5.1 Percentage of participants	6.1 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 40: Clear (n=41, 38, 79)	7.3 Percentage of participants	18.4 Percentage of participants	12.7 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 40: Almost Clear (n=41, 38, 79)	46.3 Percentage of participants	31.6 Percentage of participants	39.2 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 40: Moderate (n=41, 38, 79)	22.0 Percentage of participants	26.3 Percentage of participants	24.1 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 40: Severe (n=41, 38, 79)	4.9 Percentage of participants	5.3 Percentage of participants	5.1 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 52: Clear (n=39, 32, 71)	20.5 Percentage of participants	18.8 Percentage of participants	19.7 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 52: Almost Clear (n=39, 32, 71)	20.5 Percentage of participants	31.3 Percentage of participants	25.4 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 52: Mild (n=39, 32, 71)	28.2 Percentage of participants	25.0 Percentage of participants	26.8 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 52: Moderate (n=39, 32, 71)	15.4 Percentage of participants	21.9 Percentage of participants	18.3 Percentage of participants
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category Week 52: Severe (n=39, 32, 71)	15.4 Percentage of participants	3.1 Percentage of participants	9.9 Percentage of participants

SECONDARY outcome

Timeframe: Baseline, Week 4, 16, 28, 52

Population: The subjects with a medical history of ongoing psoriatic arthritis (that was defined as the MedDRA preferred term for psoriatic arthropathy regardless of meeting the inclusion criteria for the psoriatic arthritis) in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.

The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to "select the number that best describes any joint pain that participant may have experienced over the past 24 hours" with response options ranging from "0-no joint pain" to "10-worst possible joint pain."

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=8 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=15 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=23 Participants (=sum across Arm/Groups)
Joint Pain Assessment (JPA) Baseline	5.25 Units on a scale Standard Deviation 3.327	4.60 Units on a scale Standard Deviation 2.558	4.83 Units on a scale Standard Deviation 2.790
Joint Pain Assessment (JPA) Week 4 (n=8, 14, 22)	4.00 Units on a scale Standard Deviation 2.726	1.36 Units on a scale Standard Deviation 1.008	2.32 Units on a scale Standard Deviation 2.191
Joint Pain Assessment (JPA) Week 16 (n=8, 15, 23)	1.88 Units on a scale Standard Deviation 2.295	0.60 Units on a scale Standard Deviation 0.737	1.04 Units on a scale Standard Deviation 1.551
Joint Pain Assessment (JPA) Week 28 (n=8, 14, 22)	1.75 Units on a scale Standard Deviation 1.753	0.86 Units on a scale Standard Deviation 0.949	1.18 Units on a scale Standard Deviation 1.332
Joint Pain Assessment (JPA) Week 52 (n=4, 13, 17)	0.50 Units on a scale Standard Deviation 0.577	0.54 Units on a scale Standard Deviation 0.660	0.53 Units on a scale Standard Deviation 0.624

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 20, 28, 40, 52

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=4 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=8 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=12 Participants (=sum across Arm/Groups)
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Week 2	0.0 Percentage of participants	62.5 Percentage of participants	41.7 Percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Week 4	50.0 Percentage of participants	75.0 Percentage of participants	66.7 Percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Week 8	75.0 Percentage of participants	100 Percentage of participants	91.7 Percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Week 12	100 Percentage of participants	87.5 Percentage of participants	91.7 Percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Week 20	100 Percentage of participants	87.5 Percentage of participants	91.7 Percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Week 28	100 Percentage of participants	100 Percentage of participants	100 Percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Week 52	50.0 Percentage of participants	100 Percentage of participants	83.3 Percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Week 40	75.0 Percentage of participants	100 Percentage of participants	91.7 Percentage of participants

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

ACR50 response: greater than or equal to (\>=) 50 percent (%) improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=4 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=8 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=12 Participants (=sum across Arm/Groups)
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Week 2	0.0 Percentage of participants	25.0 Percentage of participants	16.7 Percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Week 4	25.0 Percentage of participants	50.0 Percentage of participants	41.7 Percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Week 8	50.0 Percentage of participants	62.5 Percentage of participants	58.3 Percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Week 12	75.0 Percentage of participants	75.0 Percentage of participants	75.0 Percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Week 16	75.0 Percentage of participants	87.5 Percentage of participants	83.3 Percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Week 20	100 Percentage of participants	87.5 Percentage of participants	91.7 Percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Week 28	100 Percentage of participants	75.0 Percentage of participants	83.3 Percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Week 40	75.0 Percentage of participants	87.5 Percentage of participants	83.3 Percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Week 52	50.0 Percentage of participants	87.5 Percentage of participants	75.0 Percentage of participants

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

ACR70 response: greater than or equal to (\>=) 70 percent (%) improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=4 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=8 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=12 Participants (=sum across Arm/Groups)
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Week 12	50.0 Percentage of participants	62.5 Percentage of participants	58.3 Percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Week 20	75.0 Percentage of participants	75.0 Percentage of participants	75.0 Percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Week 28	75.0 Percentage of participants	50.0 Percentage of participants	58.3 Percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Week 40	50.0 Percentage of participants	75.0 Percentage of participants	66.7 Percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Week 2	0.0 Percentage of participants	0.0 Percentage of participants	0.0 Percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Week 4	0.0 Percentage of participants	37.5 Percentage of participants	25.0 Percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Week 8	25.0 Percentage of participants	62.5 Percentage of participants	50.0 Percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Week 16	50.0 Percentage of participants	62.5 Percentage of participants	58.3 Percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Week 52	50.0 Percentage of participants	75.0 Percentage of participants	66.7 Percentage of participants

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

Sixty eight (68) joints were assessed by a rheumatologist investigator to determine the number of joints that were considered tender or painful. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=4 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=8 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=12 Participants (=sum across Arm/Groups)
Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count Week 2	-1.8 Tender/painful joints Standard Deviation 1.50	-3.5 Tender/painful joints Standard Deviation 2.78	-2.9 Tender/painful joints Standard Deviation 2.50
Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count Week 4	-6.3 Tender/painful joints Standard Deviation 6.70	-9.3 Tender/painful joints Standard Deviation 11.37	-8.3 Tender/painful joints Standard Deviation 9.84
Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count Week 16	-13.0 Tender/painful joints Standard Deviation 9.59	-13.0 Tender/painful joints Standard Deviation 12.17	-13.0 Tender/painful joints Standard Deviation 10.92
Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count Week 20	-14.3 Tender/painful joints Standard Deviation 9.11	-12.4 Tender/painful joints Standard Deviation 12.87	-13.0 Tender/painful joints Standard Deviation 11.35
Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count Week 28	-14.0 Tender/painful joints Standard Deviation 9.38	-12.4 Tender/painful joints Standard Deviation 12.52	-12.9 Tender/painful joints Standard Deviation 11.16
Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count Week 40	-14.3 Tender/painful joints Standard Deviation 10.14	-13.4 Tender/painful joints Standard Deviation 12.09	-13.7 Tender/painful joints Standard Deviation 11.02
Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count Week 52 (n=3, 8, 11)	-11.3 Tender/painful joints Standard Deviation 9.24	-13.5 Tender/painful joints Standard Deviation 12.08	-12.9 Tender/painful joints Standard Deviation 10.97
Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count Week 8	-11.5 Tender/painful joints Standard Deviation 10.08	-11.6 Tender/painful joints Standard Deviation 10.24	-11.6 Tender/painful joints Standard Deviation 9.72
Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count Week 12	-13.8 Tender/painful joints Standard Deviation 10.78	-12.5 Tender/painful joints Standard Deviation 11.95	-12.9 Tender/painful joints Standard Deviation 11.09

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

Sixty six (66) joints were assessed for swelling by a rheumatologist investigator to determine the number of joints that were considered swelling. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=4 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=8 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=12 Participants (=sum across Arm/Groups)
Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count Week 2	-1.8 Swollen joints Standard Deviation 2.22	-3.8 Swollen joints Standard Deviation 5.55	-3.1 Swollen joints Standard Deviation 4.68
Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count Week 12	-6.5 Swollen joints Standard Deviation 6.35	-7.0 Swollen joints Standard Deviation 4.44	-6.8 Swollen joints Standard Deviation 4.86
Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count Week 16	-7.3 Swollen joints Standard Deviation 7.85	-7.8 Swollen joints Standard Deviation 3.85	-7.6 Swollen joints Standard Deviation 5.12
Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count Week 40	-7.3 Swollen joints Standard Deviation 7.85	-8.8 Swollen joints Standard Deviation 4.20	-8.3 Swollen joints Standard Deviation 5.34
Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count Week 52 (n=3, 8, 11)	-3.0 Swollen joints Standard Deviation 0.00	-8.8 Swollen joints Standard Deviation 4.13	-7.2 Swollen joints Standard Deviation 4.38
Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count Week 4	-5.0 Swollen joints Standard Deviation 4.69	-5.3 Swollen joints Standard Deviation 5.80	-5.2 Swollen joints Standard Deviation 5.24
Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count Week 8	-6.0 Swollen joints Standard Deviation 7.35	-6.4 Swollen joints Standard Deviation 4.37	-6.3 Swollen joints Standard Deviation 5.19
Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count Week 20	-7.0 Swollen joints Standard Deviation 8.00	-8.9 Swollen joints Standard Deviation 4.42	-8.3 Swollen joints Standard Deviation 5.55
Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count Week 28	-7.3 Swollen joints Standard Deviation 7.85	-7.6 Swollen joints Standard Deviation 4.03	-7.5 Swollen joints Standard Deviation 5.21

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

Subjects assessed the severity of their arthritis pain with a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (the most severe pain), which corresponded to the magnitude of their pain.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=4 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=8 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=12 Participants (=sum across Arm/Groups)
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain Week 4	-13.0 Units on a scale Standard Deviation 23.41	-41.4 Units on a scale Standard Deviation 25.29	-31.9 Units on a scale Standard Deviation 27.42
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain Week 12	-34.5 Units on a scale Standard Deviation 19.71	-46.0 Units on a scale Standard Deviation 23.42	-42.2 Units on a scale Standard Deviation 22.07
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain Week 28	-45.8 Units on a scale Standard Deviation 23.26	-45.8 Units on a scale Standard Deviation 20.46	-45.8 Units on a scale Standard Deviation 20.34
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain Week 40	-20.0 Units on a scale Standard Deviation 54.86	-46.9 Units on a scale Standard Deviation 22.66	-37.9 Units on a scale Standard Deviation 36.37
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain Week 52 (n=3, 8, 11)	-33.0 Units on a scale Standard Deviation 31.19	-48.4 Units on a scale Standard Deviation 22.14	-44.2 Units on a scale Standard Deviation 24.28
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain Week 2	-13.3 Units on a scale Standard Deviation 8.30	-29.5 Units on a scale Standard Deviation 23.40	-24.1 Units on a scale Standard Deviation 20.77
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain Week 8	-16.0 Units on a scale Standard Deviation 19.78	-43.6 Units on a scale Standard Deviation 22.68	-34.4 Units on a scale Standard Deviation 24.88
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain Week 16	-27.3 Units on a scale Standard Deviation 15.22	-46.0 Units on a scale Standard Deviation 22.44	-39.8 Units on a scale Standard Deviation 21.65
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain Week 20	-44.0 Units on a scale Standard Deviation 22.82	-45.3 Units on a scale Standard Deviation 21.53	-44.8 Units on a scale Standard Deviation 20.91

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

Subjects answered the following question, "Considering the possible effects of the arthritis, how are you feeling today?" The subject's response was recorded with a 100 mm visual analog scale (VAS), where 0 = very well and 100 = very poorly.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=4 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=8 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=12 Participants (=sum across Arm/Groups)
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis Week 2	-8.0 Units on a scale Standard Deviation 8.87	-32.6 Units on a scale Standard Deviation 27.55	-24.4 Units on a scale Standard Deviation 25.53
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis Week 4	-20.5 Units on a scale Standard Deviation 11.27	-43.4 Units on a scale Standard Deviation 27.47	-35.8 Units on a scale Standard Deviation 25.33
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis Week 8	-23.3 Units on a scale Standard Deviation 19.69	-51.3 Units on a scale Standard Deviation 20.53	-41.9 Units on a scale Standard Deviation 23.75
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis Week 12	-45.0 Units on a scale Standard Deviation 8.83	-52.1 Units on a scale Standard Deviation 21.35	-49.8 Units on a scale Standard Deviation 17.99
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis Week 16	-40.0 Units on a scale Standard Deviation 13.64	-53.0 Units on a scale Standard Deviation 20.96	-48.7 Units on a scale Standard Deviation 19.27
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis Week 20	-49.5 Units on a scale Standard Deviation 20.09	-49.6 Units on a scale Standard Deviation 20.26	-49.6 Units on a scale Standard Deviation 19.27
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis Week 28	-52.3 Units on a scale Standard Deviation 11.18	-46.3 Units on a scale Standard Deviation 26.67	-48.3 Units on a scale Standard Deviation 22.26
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis Week 40	-20.8 Units on a scale Standard Deviation 30.24	-50.8 Units on a scale Standard Deviation 20.78	-40.8 Units on a scale Standard Deviation 27.24
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis Week 52 (n=3, 8, 11)	-40.7 Units on a scale Standard Deviation 16.80	-55.3 Units on a scale Standard Deviation 20.51	-51.3 Units on a scale Standard Deviation 19.94

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

The rheumatologist investigator assessed how the subject's overall arthritis appeared at the time of the visit. This was an evaluation based on the subject's disease signs, functional capacity and physical examination, and was independent of the PGA of arthritis. The rheumatologist investigator's response was recorded a 100 mm visual analog scale (VAS), where 0 = very good and 100 = very poor.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=4 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=8 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=12 Participants (=sum across Arm/Groups)
Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis Week 8	-29.5 Units on a scale Standard Deviation 30.01	-41.8 Units on a scale Standard Deviation 21.87	-37.7 Units on a scale Standard Deviation 24.21
Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis Week 12	-39.8 Units on a scale Standard Deviation 21.00	-45.8 Units on a scale Standard Deviation 22.76	-43.8 Units on a scale Standard Deviation 21.42
Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis Week 2	-15.3 Units on a scale Standard Deviation 18.01	-28.5 Units on a scale Standard Deviation 18.60	-24.1 Units on a scale Standard Deviation 18.74
Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis Week 4	-32.5 Units on a scale Standard Deviation 22.28	-34.6 Units on a scale Standard Deviation 19.39	-33.9 Units on a scale Standard Deviation 19.38
Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis Week 16	-49.8 Units on a scale Standard Deviation 23.34	-47.9 Units on a scale Standard Deviation 20.09	-48.5 Units on a scale Standard Deviation 20.16
Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis Week 28	-49.5 Units on a scale Standard Deviation 25.96	-42.8 Units on a scale Standard Deviation 22.79	-45.0 Units on a scale Standard Deviation 22.92
Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis Week 40	-38.5 Units on a scale Standard Deviation 39.03	-49.5 Units on a scale Standard Deviation 18.54	-45.8 Units on a scale Standard Deviation 25.76
Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis Week 52 (n=3, 8, 11)	-29.0 Units on a scale Standard Deviation 20.30	-46.8 Units on a scale Standard Deviation 25.08	-41.9 Units on a scale Standard Deviation 24.32
Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis Week 20	-50.8 Units on a scale Standard Deviation 25.29	-45.3 Units on a scale Standard Deviation 26.81	-47.1 Units on a scale Standard Deviation 25.28

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

The blood samples were collected at each visit for analysis of CRP with an assay analyzed by the central laboratory.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=4 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=8 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=12 Participants (=sum across Arm/Groups)
Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP) Week 2	-1.20 mg/dL Standard Deviation 2.137	-1.68 mg/dL Standard Deviation 2.231	-1.52 mg/dL Standard Deviation 2.114
Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP) Week 40 (n=4, 7, 11)	-1.15 mg/dL Standard Deviation 2.037	-1.84 mg/dL Standard Deviation 2.461	-1.59 mg/dL Standard Deviation 2.236
Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP) Week 4	-1.20 mg/dL Standard Deviation 2.267	-1.69 mg/dL Standard Deviation 2.272	-1.53 mg/dL Standard Deviation 2.178
Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP) Week 8	-1.28 mg/dL Standard Deviation 2.354	-1.70 mg/dL Standard Deviation 2.222	-1.56 mg/dL Standard Deviation 2.167
Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP) Week 12	-1.28 mg/dL Standard Deviation 2.351	-1.68 mg/dL Standard Deviation 2.235	-1.54 mg/dL Standard Deviation 2.174
Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP) Week 16	-1.30 mg/dL Standard Deviation 2.337	-1.69 mg/dL Standard Deviation 2.189	-1.56 mg/dL Standard Deviation 2.139
Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP) Week 20	-1.33 mg/dL Standard Deviation 2.387	-1.59 mg/dL Standard Deviation 2.336	-1.50 mg/dL Standard Deviation 2.246
Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP) Week 28	-1.30 mg/dL Standard Deviation 2.337	-1.15 mg/dL Standard Deviation 2.770	-1.20 mg/dL Standard Deviation 2.526
Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP) Week 52 (n=3, 8, 11)	-0.03 mg/dL Standard Deviation 0.058	-1.65 mg/dL Standard Deviation 2.295	-1.21 mg/dL Standard Deviation 2.064

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16, 20, 28, 40, 52

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.

Outcome measures

Outcome measures
Measure	CP-690,550 5 mg BID n=4 Participants CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=8 Participants CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=12 Participants (=sum across Arm/Groups)
Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI) Week 4	-0.28 Units on a scale Standard Deviation 0.329	-0.36 Units on a scale Standard Deviation 0.381	-0.33 Units on a scale Standard Deviation 0.351
Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI) Week 8	-0.28 Units on a scale Standard Deviation 0.359	-0.42 Units on a scale Standard Deviation 0.433	-0.38 Units on a scale Standard Deviation 0.399
Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI) Week 12	-0.28 Units on a scale Standard Deviation 0.359	-0.42 Units on a scale Standard Deviation 0.433	-0.38 Units on a scale Standard Deviation 0.399
Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI) Week 16	-0.31 Units on a scale Standard Deviation 0.375	-0.42 Units on a scale Standard Deviation 0.433	-0.39 Units on a scale Standard Deviation 0.400
Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI) Week 20	-0.28 Units on a scale Standard Deviation 0.359	-0.42 Units on a scale Standard Deviation 0.433	-0.38 Units on a scale Standard Deviation 0.399
Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI) Week 28	-0.34 Units on a scale Standard Deviation 0.400	-0.42 Units on a scale Standard Deviation 0.433	-0.40 Units on a scale Standard Deviation 0.405
Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI) Week 40	-0.09 Units on a scale Standard Deviation 0.640	-0.42 Units on a scale Standard Deviation 0.433	-0.31 Units on a scale Standard Deviation 0.507
Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI) Week 52 (n=3, 8, 11)	-0.13 Units on a scale Standard Deviation 0.573	-0.42 Units on a scale Standard Deviation 0.433	-0.34 Units on a scale Standard Deviation 0.465
Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI) Week 2	-0.19 Units on a scale Standard Deviation 0.239	-0.28 Units on a scale Standard Deviation 0.376	-0.25 Units on a scale Standard Deviation 0.329

Adverse Events

CP-690,550 5 mg BID

Serious events: 3 serious events

Other events: 37 other events

Deaths: 0 deaths

CP-690,550 10 mg BID

Serious events: 3 serious events

Other events: 40 other events

Deaths: 0 deaths

Total

Serious events: 6 serious events

Other events: 77 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	CP-690,550 5 mg BID n=47 participants at risk CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	CP-690,550 10 mg BID n=47 participants at risk CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.	Total n=94 participants at risk (=sum across Arm/Groups)
Ear and labyrinth disorders Vertigo	0.00% 0/47 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.1% 1/47 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	1.1% 1/94 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Herpes zoster	6.4% 3/47 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/47 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	3.2% 3/94 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Impetigo	0.00% 0/47 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.1% 1/47 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	1.1% 1/94 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Skin and subcutaneous tissue disorders Erythrodermic psoriasis	0.00% 0/47 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.1% 1/47 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	1.1% 1/94 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Skin and subcutaneous tissue disorders Psoriasis	0.00% 0/47 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.1% 1/47 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	1.1% 1/94 The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.

Other adverse events

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer, Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER